8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 4, 2021

STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)

Delaware	0-11634	95-3797439
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
25651 Atlantic Ocean Drive Lake Forest, California		92630
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	STAA	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2021, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended July 2, 2021, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

 This information and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits

Exhibit No.	Description
99.1	Press release of the Company dated August 4, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company
August 4, 2021	By:	/s/ Caren Mason
		Caren Mason
		President and Chief Executive Officer

EX-99.1

Exhibit 99.1

STAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021

Second Quarter ICL Sales Up 93% Y/Y and Units Up 79% Y/Y

Increases Full Year 2021 Net Sales Outlook to Range of $227 Million to $230 Million

LAKE FOREST, CA, August 4, 2021 ---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 2, 2021.

Second Quarter 2021 Overview

• Record Quarterly Net Sales of $62.4 Million Up 77% from the Prior Year Quarter

• Record Quarterly ICL Sales of $59.2 Million Up 93% from the Prior Year Quarter

• Record Quarterly ICL Units, Up 79% from the Prior Year Quarter

• Gross Margin at 78.9% vs. 69.4% in the Prior Year Quarter

• Net Income of $0.17 per Share vs. Prior Year Quarter Net Loss of ($0.03) per Share

• Cash and Cash Equivalents Ended the Quarter at $173.1 Million Up from $152.5 Million in Q4 2020

“STAAR’s second quarter results reflect the accelerating sales momentum and significant opportunity for our vision correction lenses. Global ICL unit growth increased 79% over the prior year quarter and we achieved positive sales and unit growth in all of our major markets. Asia, Europe, and the U.S. led our outperformance during the quarter. The Middle East, North Africa, and India, even harder hit by the pandemic than most of our developed major markets in 2020, rebounded strongly,” said Caren Mason, President and CEO of STAAR Surgical. “Following our achievement of record breaking first half 2021 results and with increasing visibility into key second half growth drivers for our business, we are today raising our outlook for full year fiscal 2021 net sales to a range of $227 million to $230 million, up from our previously provided outlook of $215 million to $217 million that we shared on May 5th. At the mid-point, our increased sales outlook for the fiscal year 2021 represents approximately 40% growth year over year.”

“Standout ICL unit growth in the second quarter, year over year, included China up 65%, Japan up 95%, Korea up 57%, Rest of Asia Pacific up 88%, Spain up 118%, Germany up 65%, Distributor Markets in Europe up 81%, and the U.S. up 255%. In China we kicked off the busy implant season with a new advertising campaign and several new and exciting marketing programs. In Spain, our ICL benefited from proprietary and premium positioning as we continued to gain market share despite increased price discounting for certain femtosecond refractive laser vision procedures. In the U.S., we sold more ICLs in the second quarter of 2021 than the entire first half of 2020. Clinical trial data for our EVO family of myopia lenses is under customary interactive review by the FDA and our goal remains to bring EVO to the U.S. market later this year. Finally, in-person ophthalmic industry sales meetings and trade shows resumed in earnest last month, including the American-European Congress of Ophthalmic Surgery (AECOS) meeting in Deer Valley, UT, andthe American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, in Las Vegas, NV. ASCRS was preceded by Eyecelerator, a meeting dedicated to showcasing and advancing ophthalmic innovations. Our proprietary Implantable Collamer® Lenses were prominently and positively showcased at all three

1

meetings, and more so than at any point in the past,as further evidence of a coming lens-based future for refractive vision correction,” concluded Ms. Mason.

Financial Overview – Q2 2021

Net sales were $62.4 million for the second quarter of 2021, up 77% compared to $35.2 million reported in the prior year quarter. The sales increase was driven by ICL net sales and unit growth up 93% and 79%, respectively, as compared to the prior year period. ICL net sales were 95% of total net sales for the second quarter of 2021. Other Product Sales were $3.1 million, representing 5% of total net sales and decreased 30% compared to the prior year quarter due primarily to lower sales of low margin injector parts.

Gross profit margin for the second quarter of 2021 was 78.9% compared to the prior year period of 69.4%. Factors positively impacting gross margin in the second quarter of 2021, as compared to the prior year period, include geographic sales mix and a decreased mix of injector part sales which carry a lower margin, and for the three months ended July 3, 2020, there were period costs recorded as a result of COVID-19 and the resulting voluntary manufacturing pause which concluded on April 26, 2020.

Operating expenses for the second quarter of 2021 were $38.6 million compared to the prior year quarter of $25.5 million. General and administrative expenses were $11.4 million compared to the prior year quarter of $7.8 million. The increase in general and administrative expenses was due to increased compensation-related expenses, corporate insurance and facilities costs. Selling and marketing expenses were $18.9 million compared to the prior year quarter of $10.3 million. The increase in selling and marketing expenses is due to increased compensation-related expenses, advertising and promotional activities, trade show expenses and travel expenses. Research and development expenses were $8.3 million compared to the prior year quarter of $7.3 million. The increase in research and development expenses is primarily due to increased compensation-related expenses, partially offset by lower expenses associated with the EVO clinical trial in the U.S.

Net income for the second quarter of 2021 was $8.6 million or $0.17 per diluted share compared with net loss of ($1.2) million or ($0.03) per diluted share for the prior year quarter. Adjusted Net Income for the second quarter of 2021 was $13.5 million or $0.27 per diluted share compared to $1.4 million or $0.03 per diluted share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash and cash equivalents at July 2, 2021 totaled $173.1 million compared to $152.5 million at January 1, 2021. 

Conference Call

The Company will host a conference call and webcast today, Wednesday, August 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 6090849), please dial 866-209-9722 for domestic participants and 825-312-2235 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 6090849) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 800-585-8367 for domestic callers and 416-621-4642 for international callers. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. “Adjusted Net Income” excludes the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”):

2

gain or loss on foreign currency transactions, stock-based compensation expenses, and valuation allowance adjustments.  Management believes that “Adjusted Net Income” is useful to investors in gauging the outcome of the key drivers of the business performance:  the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.

Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718.  Valuation allowance adjustments can occur from time to time based on forecasted changes in operating results until all net operating loss carryforwards are fully utilized.  In calculating Adjusted Net Income, STAAR excludes these expenses because they are non-cash expenses and because of the considerable judgment involved in calculating their values.  In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.  

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian^® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2021 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to its impact on sales, operations or clinical trials globally), product safety or effectiveness, the status of our pipeline of ICL products with regulators, including our EVO family of lenses in the U.S., and any statements of assumptions underlying any of the foregoing, including those relating to our product pipeline and market expansion activities. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks

3

and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended January 1, 2021 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The EVO version of our ICL lens is not yet approved for sale in the United States.

CONTACT:Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

4

Consolidated Balance Sheets

(in 000's)

Unaudited

ASSETS	July 2, 2021			January 1, 2021
Current assets:
Cash and cash equivalents	$	173,083		$	152,453
Accounts receivable trade, net		48,647			35,229
Inventories, net		15,590			18,111
Prepayments, deposits, and other current assets		10,797			10,625
Total current assets		248,117			216,418
Property, plant, and equipment, net		28,616			24,030
Finance lease right-of-use assets, net		59			596
Operating lease right-of-use assets, net		11,243			8,764
Intangible assets, net		239			270
Goodwill		1,786			1,786
Deferred income taxes		3,720			4,944
Other assets		658			608
Total assets	$	294,438		$	257,416
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit	$	1,280		$	1,379
Accounts payable		7,579			7,874
Obligations under finance leases		85			360
Obligations under operating leases		2,765			2,485
Allowance for sales returns		5,429			4,532
Other current liabilities		24,663			24,606
Total current liabilities		41,801			41,236
Obligations under finance leases		25			38
Obligations under operating leases		8,654			6,537
Deferred income taxes		222			222
Asset retirement obligations		205			221
Pension liability		8,909			11,940
Total liabilities		59,816			60,194
Stockholders' equity:
Common stock		474			464
Additional paid-in capital		360,316			338,194
Accumulated other comprehensive loss		(3,836	)		(5,545	)
Accumulated deficit		(122,332	)		(135,891	)
Total stockholders' equity		234,622			197,222
Total liabilities and stockholders' equity	$	294,438		$	257,416

5

Consolidated Statements of Operations

(In 000's except for per share data)

Unaudited

	Three Months Ended																		Six Months Ended
	% of			July 2, 2021			% of			July 3, 2020			Fav (Unfav)						% of			July 2, 2021			% of			July 3, 2020			Fav (Unfav)
	Sales						Sales						Amount			%			Sales						Sales						Amount			%
Net sales		100.0	%	$	62,367			100.0	%	$	35,194		$	27,173			77.2	%		100.0	%	$	113,119			100.0	%	$	70,381		$	42,738			60.7	%
Cost of sales		21.1	%		13,164			30.6	%		10,764			(2,400	)		-22.3	%		21.9	%		24,774			30.1	%		21,191			(3,583	)		-16.9	%
Gross profit		78.9	%		49,203			69.4	%		24,430			24,773			101.4	%		78.1	%		88,345			69.9	%		49,190			39,155			79.6	%
Selling, general and administrative expenses:
General and administrative		18.4	%		11,441			22.3	%		7,848			(3,593	)		-45.8	%		19.1	%		21,653			22.5	%		15,817			(5,836	)		-36.9	%
Selling and marketing		30.2	%		18,853			29.3	%		10,326			(8,527	)		-82.6	%		28.4	%		32,054			30.3	%		21,354			(10,700	)		-50.1	%
Research and development		13.2	%		8,260			20.8	%		7,311			(949	)		-13.0	%		14.6	%		16,519			20.2	%		14,209			(2,310	)		-16.3	%
Total selling, general, and administrative expenses		61.8	%		38,554			72.4	%		25,485			(13,069	)		-51.3	%		62.1	%		70,226			73.0	%		51,380			(18,846	)		-36.7	%
Operating income (loss)		17.1	%		10,649			-3.0	%		(1,055	)		11,704			1109.4	%		16.0	%		18,119			-3.1	%		(2,190	)		20,309			927.4	%
Other expense:
Interest income (expense), net		0.0	%		(5	)		0.1	%		20			(25	)		-125.0	%		0.0	%		(12	)		0.3	%		236			(248	)		-105.1	%
Gain (loss) on foreign currency transactions		-0.2	%		(131	)		1.1	%		388			(519	)		-133.8	%		-1.3	%		(1,430	)		-0.1	%		(80	)		(1,350	)		-1687.5	%
Royalty income		0.2	%		151			0.1	%		52			99			190.4	%		0.3	%		311			0.2	%		146			165			113.0	%
Other income (expense), net		0.1	%		51			-0.1	%		(21	)		72			342.9	%		0.0	%		(34	)		0.0	%		(20	)		(14	)		-70.0	%
Total other income (expense), net		0.1	%		66			1.2	%		439			(373	)		-85.0	%		-1.0	%		(1,165	)		0.4	%		282			(1,447	)		-513.1	%
Income (loss) before provision (benefit) for income taxes		17.2	%		10,715			-1.8	%		(616	)		11,331			1839.4	%		15.0	%		16,954			-2.7	%		(1,908	)		18,862			988.6	%
Provision (benefit) for income taxes		3.5	%		2,148			1.5	%		556			(1,592	)		-286.3	%		3.0	%		3,395			-0.8	%		(602	)		(3,997	)		-664.0	%
Net income (loss)		13.7	%	$	8,567			-3.3	%	$	(1,172	)	$	9,739			831.0	%		12.0	%	$	13,559			-1.9	%	$	(1,306	)	$	14,865			1138.2	%
Net income (loss) per share - basic				$	0.18					$	(0.03	)										$	0.29					$	(0.03	)
Net income (loss) per share - diluted				$	0.17					$	(0.03	)										$	0.27					$	(0.03	)
Weighted average shares outstanding - basic					47,099						45,354												46,858						45,152
Weighted average shares outstanding - diluted					49,491						45,354												49,373						45,152

6

Consolidated Statements of Cash Flows

(in 000's)

Unaudited

	Three Months Ended						Six Months Ended
	July 2, 2021			July 3, 2020			July 2, 2021			July 3, 2020
Cash flows from operating activities:
Net income (loss)	$	8,567		$	(1,172	)	$	13,559		$	(1,306	)
Adjustments to reconcile net income (loss) to net cash     provided by (used in) operating activities:
Depreciation of property and equipment		889			752			1,754			1,518
Amortization of long-lived intangibles		8			8			17			17
Deferred income taxes		845			-			845			(1,369	)
Change in net pension liability		(154	)		203			(27	)		376
Stock-based compensation expense		3,992			2,918			7,322			5,839
Loss on disposal of property and equipment		-			-			2			3
Provision for sales returns and bad debts		829			525			932			605
Inventory provision		313			480			697			816
Changes in working capital:
Accounts receivable		(14,935	)		(4,947	)		(13,797	)		(8,409	)
Inventories		1,254			(441	)		2,238			(932	)
Prepayments, deposits and other current assets		(164	)		274			(307	)		(2,172	)
Accounts payable		131			(610	)		(268	)		297
Other current liabilities		4,807			1,993			181			(3,471	)
Net cash provided by (used in) operating activities		6,382			(17	)		13,148			(8,188	)
Cash flows from investing activities:
Acquisition of property and equipment		(3,524	)		(2,025	)		(5,683	)		(4,210	)
Net cash used in investing activities		(3,524	)		(2,025	)		(5,683	)		(4,210	)
Cash flows from financing activities:
Repayment on line of credit		-			(3	)		-			(508	)
Repayment of finance lease obligations		(43	)		(110	)		(278	)		(346	)
Proceeds from vested restricted stock and exercise of stock options		7,876			7,553			14,111			9,558
Net cash provided by financing activities		7,833			7,440			13,833			8,704
Effect of exchange rate changes on cash and cash equivalents		48			66			(668	)		41
Increase (decrease) in cash and cash equivalents		10,739			5,464			20,630			(3,653	)
Cash and cash equivalents, at beginning of the period		162,344			110,851			152,453			119,968
Cash and cash equivalents, at end of the period	$	173,083		$	116,315		$	173,083		$	116,315

7

Reconciliation of Non-GAAP Financial Measure

Adjusted Net Income (Loss) and Net Income (Loss) Per Share

(in 000's)

Unaudited

	Three Months Ended					Six Months Ended
	July 2, 2021		July 3, 2020			July 2, 2021		July 3, 2020
Net income (loss) (as reported)	$	8,567	$	(1,172	)	$	13,559	$	(1,306	)
Less:
Foreign currency impact		131		(388	)		1,430		80
Stock-based compensation expense		3,992		2,918			7,322		5,839
Valuation allowance adjustment		845		-			845		(1,369	)
Net income (adjusted)	$	13,535	$	1,358		$	23,156	$	3,244
Net income (loss) per share, basic (as reported)	$	0.18	$	(0.03	)	$	0.29	$	(0.03	)
Foreign currency impact		-		-			0.03		-
Stock-based compensation expense		0.09		0.06			0.15		0.13
Valuation allowance adjustment		0.02		-			0.02		(0.03	)
Net income per share, basic (adjusted)	$	0.29	$	0.03		$	0.49	$	0.07
Net income (loss) per share, diluted (as reported)	$	0.17	$	(0.03	)	$	0.27	$	(0.03	)
Foreign currency impact		-		-			0.03		-
Stock-based compensation expense		0.08		0.06			0.15		0.12
Valuation allowance adjustment		0.02		-			0.02		(0.02	)
Net income per share, diluted (adjusted)	$	0.27	$	0.03		$	0.47	$	0.07
Weighted average shares outstanding - Basic		47,099		45,354			46,858		45,152
Weighted average shares outstanding - Diluted		49,491		47,546			49,373		47,328

Note: Net income per share (adjusted), basic and diluted, may not add due to rounding

8

STAAR Surgical Company

Reconciliation of Non-GAAP Financial Measure

Constant Currency Sales

(in 000's)

Unaudited

	Three Months Ended
	July 2, 2021		Effect of			Constant		July 3, 2020		As Reported						Constant Currency
Sales			Currency			Currency				$ Change			% Change			$ Change			% Change
ICL	$	59,235	$	(738	)	$	58,497	$	30,728	$	28,507			92.8	%	$	27,769			90.4	%
IOL		3,074		(58	)		3,016		2,561		513			20.0	%		455			17.8	%
Other		58		20			78		1,905		(1,847	)		-97.0	%		(1,827	)		-95.9	%
Other Products		3,132		(38	)		3,094		4,466		(1,334	)		-29.9	%		(1,372	)		-30.7	%
Total Sales	$	62,367	$	(776	)	$	61,591	$	35,194	$	27,173			77.2	%	$	26,397			75.0	%
	Six Months Ended
	July 2, 2021		Effect of			Constant		July 3, 2020		As Reported						Constant Currency
Sales			Currency			Currency				$ Change			% Change			$ Change			% Change
ICL	$	105,736	$	(1,722	)	$	104,014	$	60,068	$	45,668			76.0	%	$	43,946			73.2	%
IOL		6,799		(232	)		6,567		6,555		244			3.7	%		12			0.2	%
Other		584		11			595		3,758		(3,174	)		-84.5	%		(3,163	)		-84.2	%
Other Products		7,383		(221	)		7,162		10,313		(2,930	)		-28.4	%		(3,151	)		-30.6	%
Total Sales	$	113,119	$	(1,943	)	$	111,176	$	70,381	$	42,738			60.7	%	$	40,795			58.0	%

9

XML

Document And Entity Information	Aug. 04, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 04, 2021
Entity Registrant Name	STAAR Surgical Co
Entity Central Index Key	0000718937
Entity Emerging Growth Company	false
Entity File Number	0-11634
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3797439
Entity Address, Address Line One	25651 Atlantic Ocean Drive
Entity Address, City or Town	Lake Forest
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92630
City Area Code	626
Local Phone Number	303-7902
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of each class	Common
Trading Symbol(s)	STAA
Name of each exchange on which registered	NASDAQ